Status:
UNKNOWN
Comparative Analysis of the Th17 Cellular Response in Active and Inactive Pemphigus Vulgaris Patients
Lead Sponsor:
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Collaborating Sponsors:
Hospital General Dr. Manuel Gea González
Conditions:
Pemphigus Vulgaris
Bullous Dermatoses
Eligibility:
All Genders
18+ years
Brief Summary
This study will compare the pattern of Th17 immune response in active and inactive pemphigus subjects. Skin and serum samples will be taken at the moment of enrollment.
Detailed Description
Pemphigus is an autoimmune disease characterized by production of autoantibodies against desmogleins 1 and 3, which are part of the epidermis desmosomes. The first line of treatment are corticosteroid...
Eligibility Criteria
Inclusion
- Current cutaneous activity of pemphigus
- Subjects will be treated with corticosteroids with or without adjuvants
- Accept and sign the informed consent
Exclusion
- Pregnancy
- Concurrent autoimmune diseases with skin lesions
- Concurrent diagnosis of cancer
- Concurrent active infectious disease
Key Trial Info
Start Date :
June 29 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 28 2023
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT04096222
Start Date
June 29 2021
End Date
March 28 2023
Last Update
August 10 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital General Dr. Manuel Gea González
Mexico City, Mexico, 14080
2
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Mexico City, Mexico, 14080